EPZ-6438,
tazemetostat,
Tazemetostat,
EPZ-6438,
1403254-99-8,
EPZ6438,
UNII-Q40W93WPE1,
EPZ 6438,
N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide,
Q40W93WPE1,
E7438,
E-7438,
(1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-,
N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide,
Tazemetostat [INN],
[1,1'-Biphenyl]-3-carboxamide, N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-5-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-4-methyl-4'-(4-morpholinylmethyl)-,
Tazemetostat [USAN],
E 7438,
Tazemetostat(EPZ-6438),
Tazemetostat (EPZ-6438),
GTPL7011,
CHEMBL3414621,
SCHEMBL13276848,
SCHEMBL19325409,
KS-00000SRW,
EX-A509,
NSQSAUGJQHDYNO-UHFFFAOYSA-N,
HMS3653O07,
AOB87748,
EPZ-7438,
2399AH,
ABP001111,
MFCD24849415,
s7128,
AKOS026750211,
ZINC100285161,
ACN-029397,
CS-1758,
DB12887,
SB22955,
NCGC00381562-10,
4CA-0507,
AK317596,
BC600303,
HY-13803,
N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide,
QC-11696,
FT-0700193,
SW220030-1,
A12712,
J-690163,
J-690164,
(R,Z)-1-(1-(1-(ethylsulfonyl)piperidin-4-yl)ethyl)-N-((2-hydroxy-4-methoxy-6-methylpyridin-3-yl)methyl)-2-methyl-1H-indole-3-carbimi dic acid,
5-(Ethyl(tetrahydro-2H-pyran-4-yl)amino)-N-((2-hydroxy-4,6-dimethylpyridin-3-yl)methyl)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide,
N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl) methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide,
N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)biphenyl-3-carboxamide,
Lorlatinib,
D00EQL,
C34H44N4O4,
A8221,